Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Cash (2016 - 2025)

Historic Change in Cash for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Change in Cash rose 354.08% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 44301.57%. This contributed to the annual value of $10.4 million for FY2024, which is 5692.55% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Change in Cash stood at -$1.8 million, which was up 354.08% from -$5.6 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Change in Cash's 5-year high stood at $23.5 million during Q1 2021, with a 5-year trough of -$46.1 million in Q3 2022.
  • Its 5-year average for Change in Cash is $410210.5, with a median of -$1.2 million in 2021.
  • Examining YoY changes over the last 5 years, Lineage Cell Therapeutics' Change in Cash showed a top increase of 793174.06% in 2021 and a maximum decrease of 1062291.67% in 2021.
  • Lineage Cell Therapeutics' Change in Cash (Quarter) stood at -$5.1 million in 2021, then tumbled by 164.52% to -$13.4 million in 2022, then soared by 129.88% to $4.0 million in 2023, then soared by 352.1% to $18.0 million in 2024, then tumbled by 109.96% to -$1.8 million in 2025.
  • Its Change in Cash was -$1.8 million in Q3 2025, compared to -$5.6 million in Q2 2025 and $2.0 million in Q1 2025.